<i>POLRMT</i> as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients

<i>POLRMT</i> as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients

Anthracyclines are among the most used chemotherapeutic agents in breast cancer (BC). However their use is hampered by anthracycline-induced cardiotoxicity (AIC). The currently known clinical and genetic risk factors do not fully explain the observed inter-individual variability and only have a limi...

Full description

Saved in:
Bibliographic Details
Main Authors: Alejandro Velasco-Ruiz, Rocio Nuñez-Torres, Guillermo Pita, Hans Wildiers, Diether Lambrechts, Sigrid Hatse, Danielle Delombaerde, Thomas Van Brussel, M. Rosario Alonso, Nuria Alvarez, Belen Herraez, Christof Vulsteke, Pilar Zamora, Teresa Lopez-Fernandez, Anna Gonzalez-Neira
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
anthracyclines
cardiotoxicity
epirubicin
breast cancer
adverse drug reaction
<i>POLRMT</i>
Pharmacy and materia medica
RS1-441
Online Access:https://doaj.org/article/fc41170d71e949d6a10cde030ad32cba
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items